NCT03424473No Longer Available不适用
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- Seagen Inc.
研究概览
简要总结
Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information (medinfo@seagen.com).
研究设计
- 研究类型
- Expanded Access
入排标准
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
Available
不适用
Expanded Access to TipifarnibHRAS Mutations or Peripheral T Cell Lymphoma (PTCL)NCT04809233Kura Oncology, Inc.
Available
不适用
Expanded Access to ZiftomenibAcute Lymphoblastic Leukemia, With Appropriate MutationsAcute Myeloid Leukemia, With NPM1 MutationsAcute Lymphoblastic Leukemia, With KMT2A RearrangementsAcute Myeloid Leukemia, With KMT2A RearrangementsNCT05738538Kura Oncology, Inc.
No Longer Available
不适用
Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene FusionsCancers With NTRK, ROS1, or ALK Gene FusionsNCT03066661Hoffmann-La Roche
撤回
1 期
Tucatinib + Abemaciclib + Herceptin for HER2+ MBCBreast CancerNCT03846583Dana-Farber Cancer Institute
进行中（未招募）
1 期
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.HER2-positive Metastatic Breast CancerNCT05230810Criterium, Inc.40